Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

Nature Cancer · Published 2026-05-15 · DOI 10.1038/s43018-026-01172-9

Free full text

Authors (29)

Anuradha Jayaram, Memuna Rashid, Alison H. M. Reid, Francesco Orlando, Suparna Thakali, Leila Zakka, Miriam Goncalves, Jacqueline O’Dwyer, Constantine Alifrangis, Rob Jones, Elias Pintus, Sarah Needleman, Diletta Bianchini, Anna Wingate, Kenrick Ng, Mark Linch, Ursula McGovern, John Staffurth, Simon J. Crabb, Susannah Brock, Alison Birtle, Osvaldas Vainauskas, Gianmarco Leone, Millenn Chiwewe, Allan Hackshaw, Andre Lopes, Daniel Wetterskog, Francesca Demichelis, Gerhardt Attard

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Jayaram, A., Rashid, M., Reid, A., et al. (2026). Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study. Nature Cancer. https://doi.org/10.1038/s43018-026-01172-9

Related articles